Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline, Journal of Clinical Oncology, vol.32, issue.18, pp.1941-1967, 2014. ,
Current guidelines in the management of ureteric calculi, 2016. ,
Adverse effects of antiepileptic drugs, The Lancet Neurology, vol.11, issue.9, pp.792-802, 2012. ,
Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs, Acta Neurologica Scandinavica, vol.135, issue.1, pp.80-87, 2016. ,
Systematic screening allows reduction of adverse antiepileptic drug effects: A randomized trial, Neurology, vol.62, issue.1, pp.23-27, 2004. ,
Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use, Expert Review of Neurotherapeutics, vol.16, issue.11, pp.1263-1277, 2016. ,
Gabapentin, Antiepileptic Drugs, Pharmacopoeia, pp.27-29, 2010. ,
The Neurontin Legacy ? Marketing through Misinformation and Manipulation, New England Journal of Medicine, vol.360, issue.2, pp.103-106, 2009. ,
The mechanisms of action of gabapentin and pregabalin, Current Opinion in Pharmacology, vol.6, issue.1, pp.108-113, 2006. ,
, Works Cited, Globalization and Human Rights, pp.257-300, 2019.
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision, European Journal of Neurology, vol.17, issue.9, pp.1113-e88, 2010. ,
Gabapentin for chronic neuropathic pain in adults, Cochrane Database Syst Rev, vol.6, p.7938, 2017. ,
Gabapentin, Annals of Pharmacotherapy, vol.50, issue.3, pp.229-233, 2015. ,
Gabapentin misuse, abuse and diversion: a systematic review, Addiction, vol.111, issue.7, pp.1160-1174, 2016. ,
Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS), Research in Social and Administrative Pharmacy, vol.15, issue.8, pp.953-958, 2019. ,
Pregabalin: A Review of its Use in Adults with Generalized Anxiety Disorder, CNS Drugs, vol.28, issue.9, pp.835-854, 2014. ,
Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: a comparative meta-analysis, European Journal of Neurology, vol.24, issue.12, pp.1446-1456, 2017. ,
Pregabalin in acute and chronic pain, J Anaesthesiol Clin Pharmacol, vol.27, pp.307-314, 2011. ,
3-Substituted GABA analogs with central nervous system activity: A review, Medicinal Research Reviews, vol.19, issue.2, pp.149-177, 1999. ,
Pregabalin: a new anxiolytic, Expert Opinion on Investigational Drugs, vol.12, issue.4, pp.663-672, 2003. ,
Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis, Canadian Medical Association Journal, vol.190, issue.26, pp.E786-E793, 2018. ,
Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials, PLOS Medicine, vol.14, issue.8, p.e1002369, 2017. ,
Pregabalin for the Management of Neuropathic Pain in Adults with Cancer: A Systematic Review of the Literature, Pain Medicine, vol.14, issue.11, pp.1681-1688, 2013. ,
Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults, Cochrane Database of Systematic Reviews, 2013. ,
The Prevention of Chronic Postsurgical Pain Using Gabapentin and Pregabalin, Anesthesia & Analgesia, vol.115, issue.2, pp.428-442, 2012. ,
Pharmacotherapy for the prevention of chronic pain after surgery in adults, Cochrane Database of Systematic Reviews, p.8307, 2013. ,
Pregabalin for neuropathic pain in adults, Cochrane Database of Systematic Reviews, vol.1, p.7076, 2019. ,
A randomized, double-blind, placebo-controlled trial and open-label extension study to evaluate the efficacy and safety of pregabalin in the treatment of neuropathic pain associated with human immunodeficiency virus neuropathy, Pain, vol.155, issue.10, pp.1943-1954, 2014. ,
Efficacy and safety of mirogabalin for the treatment of fibromyalgia: results from three 13-week randomized, double-blind, placebo- and active-controlled, parallel-group studies and a 52-week open-label extension study, Current Medical Research and Opinion, vol.35, issue.10, pp.1825-1835, 2019. ,
Efficacy of Mirogabalin (DS-5565) on Patient-Reported Pain and Sleep Interference in Patients with Diabetic Neuropathic Pain: Secondary Outcomes of a Phase II Proof-of-Concept Study, Pain Medicine, vol.18, pp.2198-2207, 2017. ,
Abuse potential of mirogabalin in recreational polydrug users, Therapeutic Advances in Drug Safety, vol.10, p.204209861983603, 2019. ,
An in vitro investigation of the action of lamotrigine on neuronal voltage-activated sodium channels, Epilepsy Res, vol.13, pp.107-112, 1992. ,
Cav2.3 (R-Type) Calcium Channels are Critical for Mediating Anticonvulsive and Neuroprotective Properties of Lamotrigine In Vivo, Cellular Physiology and Biochemistry, vol.44, issue.3, pp.935-947, 2017. ,
Double-Blind, Placebo-Controlled Trial of Lamotrigine in Combination with Other Medications for Neuropathic Pain, Journal of Pain and Symptom Management, vol.34, issue.4, pp.446-454, 2007. ,
Synthesis and Anticonvulsant Activities ofN-Benzyl-2-acetamidopropionamide Derivatives, Journal of Medicinal Chemistry, vol.39, issue.9, pp.1907-1916, 1996. ,
Update on Antiepileptic Drugs 2019, CONTINUUM: Lifelong Learning in Neurology, vol.25, issue.2, pp.508-536, 2019. ,
Levetiracetam does not modulate neuronal voltage-gated Na+and T-type Ca2+currents, Seizure, vol.10, issue.4, pp.279-286, 2001. ,
Selective Blockade of N-Type Calcium Channels by Levetiracetam, Epilepsia, vol.43, issue.1, pp.9-18, 2002. ,
The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam, Proceedings of the National Academy of Sciences, vol.101, issue.26, pp.9861-9866, 2004. ,
489 THE ANTICONVULSANT LEVETIRACETAM FOR THE TREATMENT OF PAIN IN POLYNEUROPATHY. A RANDOMIZED, PLACEBO-CONTROLLED, CROSS-OVER TRIAL, European Journal of Pain Supplements, vol.4, issue.S1, pp.138-138, 2010. ,
Effect of levetiracetam on the postmastectomy pain syndrome, European Journal of Neurology, vol.15, issue.8, pp.851-857, 2008. ,
Sodium valproate: Kinetic profile and effects on GABA levels in various brain areas of the rat, Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol.6, issue.3, pp.223-233, 1982. ,
Valproic acid suppresses the synaptic response mediated by the NMDA receptors in rat amygdalar slices, Brain Research Bulletin, vol.33, issue.3, pp.333-336, 1994. ,
Valproate Reduces Excitability by Blockage of Sodium and Potassium Conductance, Epilepsia, vol.27, issue.3, pp.177-182, 1986. ,
Pharmacological and Therapeutic Properties of Valproate, CNS Drugs, vol.16, issue.10, pp.695-714, 2002. ,
,
Discussion: ?Half Sommerfeld Approximation for Finite Journal Bearings? (Fedor, J. V., 1963, ASME J. Basic Eng., 85, pp. 435?438), Journal of Basic Engineering, vol.85, issue.3, pp.438-438, 1963. ,
Management of diabetic neuropathy by sodium valproate and glyceryl trinitrate spray: A prospective double-blind randomized placebo-controlled study, Diabetes Research and Clinical Practice, vol.83, issue.3, pp.371-378, 2009. ,
Zonisamide: A review of the clinical and experimental evidence for its use in Parkinson?s disease, Indian Journal of Pharmacology, vol.45, issue.6, p.547, 2013. ,
Zonisamide enhances slow sodium inactivation inMyxicola, Brain Research, vol.413, issue.1, pp.185-188, 1987. ,
T-type calcium channels in neuropathic pain, PAIN, vol.157, issue.1, pp.S15-S22, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01942457
Works Cited, Hidden Treasure, pp.19-22, 2019. ,
Ethosuximide intoxication caused by interaction with isoniazid, Neurology, vol.33, issue.9, pp.1227-1227, 1983. ,
Ethosuximide in epileptic women during pregnancy and lactation period. Placental transfer, serum concentrations in nursed infants and clinical status., British Journal of Clinical Pharmacology, vol.18, issue.5, pp.671-677, 1984. ,
Randomized, controlled, dose-ranging trial of carisbamate for partial-onset seizures, Neurology, vol.71, issue.20, pp.1586-1593, 2008. ,
Carisbamate, a novel neuromodulator, inhibits voltage-gated sodium channels and action potential firing of rat hippocampal neurons, Epilepsy Research, vol.83, issue.1, pp.66-72, 2009. ,
Carisbamate (RWJ-333369) inhibits glutamate transmission in the granule cell of the dentate gyrus, Neuropharmacology, vol.61, issue.8, pp.1239-1247, 2011. ,
Modulation of the Antidepressant-Like Effects of Sustained Administration of Carisbamate and Lamotrigine on Monoaminergic Systems: Electrophysiological Studies in the Rat Brain, Journal of Pharmacology and Experimental Therapeutics, vol.347, issue.2, pp.487-496, 2013. ,
Carisbamate blockade of T-type voltage-gated calcium channels, Epilepsia, vol.58, issue.4, pp.617-626, 2017. ,
A randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of adjunctive carisbamate treatment in patients with partial-onset seizures, Epilepsia, vol.52, issue.4, pp.816-825, 2011. ,
Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo-controlled trials, Epilepsia, vol.51, issue.3, pp.333-343, 2010. ,
Carisbamate, a new carbamate for the treatment of epilepsy, IDrugs, vol.10, pp.720-727, 2007. ,
Oxcarbazepine versus phenytoin monotherapy for epilepsy, Cochrane Database of Systematic Reviews, vol.003615, 2013. ,
Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures, Cochrane Database of Systematic Reviews, vol.006453, 2009. ,
Oxcarbazepine: Mechanisms of Action, Epilepsia, vol.35, issue.s3, pp.S5-S9, 1994. ,
Action of GP 47779, the Active Metabolite of Oxcarbazepine, on the Corticostriatal System. II. Modulation of High-Voltage-Activated Calcium Currents, Epilepsia, vol.36, issue.10, pp.997-1002, 1995. ,
Carbamazepine for chronic neuropathic pain and fibromyalgia in adults, Cochrane Database of Systematic Reviews, p.5451, 2014. ,
The Response of Neuropathic Pain and Pain in Complex Regional Pain Syndrome I to Carbamazepine and Sustained-Release Morphine in Patients Pretreated with Spinal Cord Stimulation: A Double-Blinded Randomized Study, Anesthesia and Analgesia, vol.92, issue.2, pp.488-495, 2001. ,
Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study, European Journal of Pain, vol.9, issue.5, pp.543-543, 2005. ,
The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: A randomised, double-blind, placebo-controlled phenotype-stratified study, Pain, vol.155, issue.11, pp.2263-2273, 2014. ,
Neuropathic pain clinical trials, PAIN, vol.159, issue.11, pp.2339-2346, 2018. ,
Duloxetine (Cymbalta?), a dual inhibitor of serotonin and norepinephrine reuptake, Bioorganic & Medicinal Chemistry Letters, vol.13, issue.24, pp.4477-4480, 2003. ,
The Dual Transporter Inhibitor Duloxetine: A Review of its Preclinical Pharmacology, Pharmacokinetic Profile, and Clinical Results in Depression, Current Pharmaceutical Design, vol.11, issue.12, pp.1475-1493, 2005. ,
Block of Neuronal Na+Channels by Antidepressant Duloxetine in a State-dependent Manner, Anesthesiology, vol.113, issue.3, pp.655-665, 2010. ,
Safety-Related Drug Labeling Changes Approved by FDA, 1997. ,
Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative, Biochemical Pharmacology, vol.35, issue.24, pp.4493-4497, 1986. ,
NDA 22-256 Savella Addendum to Division Director Review and Summary Basis for Approval Recommendation [Internet]. Food and Drug Administration, 2009. ,
Half a Century of Antidepressant Drugs, Journal of Clinical Psychopharmacology, vol.28, issue.1, pp.1-4, 2008. ,
Pharmacological profile of antidepressants and related compounds at human monoamine transporters, European Journal of Pharmacology, vol.340, issue.2-3, pp.249-258, 1997. ,
Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites, J. Pharmacol. Exp. Ther, vol.283, pp.1305-1322, 1997. ,
Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor, J. Pharmacol. Exp. Ther, vol.299, pp.83-89, 2001. ,
Tricyclic antidepressants and dextromethorphan bind with higher affinity to the phencyclidine receptor in the absence of magnesium and L-glutamate, Mol. Pharmacol, vol.36, pp.160-165, 1989. ,
Inhibition of neuronal Na+ channels by antidepressant drugs, J. Pharmacol. Exp. Ther, vol.284, pp.208-214, 1998. ,
Amitriptyline Is a Potent Blocker of Human Kv1.1 and Kv7.2/7.3 Channels, Anesthesia & Analgesia, vol.104, issue.5, pp.1256-1264, 2007. ,
Amitriptyline is a TrkA and TrkB Receptor Agonist that Promotes TrkA/TrkB Heterodimerization and Has Potent Neurotrophic Activity, Chemistry & Biology, vol.16, issue.6, pp.644-656, 2009. ,
Clinical pharmacology review of escitalopram for the treatment of depression, Expert Opinion on Drug Metabolism & Toxicology, vol.10, issue.1, pp.121-128, 2013. ,
Drug-Induced Insomnia and Excessive Sleepiness, Sleep Medicine Clinics, vol.13, issue.2, pp.147-159, 2018. ,
Medication-Related Dizziness in the Older Adult, Otolaryngologic Clinics of North America, vol.44, issue.2, pp.455-471, 2011. ,
A Retrospective Database Analysis of Neuropathic Pain and Oral Antidiabetic Medication Use and Adherence Among Texas Adults With Type 2 Diabetes Enrolled in Medicaid, Clinical Therapeutics, vol.34, issue.3, pp.605-613, 2012. ,
Prevalence and determinants of medication non-adherence in chronic pain patients: a systematic review, Acta Anaesthesiologica Scandinavica, vol.60, issue.4, pp.416-431, 2016. ,
The impact of communication on adherence in pain management, Pain, vol.154, issue.1, pp.S101-S107, 2013. ,
Drug safety assessment in clinical trials: methodological challenges and opportunities, Trials, vol.13, issue.1, p.138, 2012. ,
Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches, Drug Safety, vol.40, issue.7, pp.547-558, 2017. ,
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials, BMJ, vol.340, issue.mar23 1, pp.c332-c332, 2010. ,
Current guidelines for double-blind, placebo-controlled ,
Duloxetine 60 mg once daily in the treatment of milder major depressive disorder, International Journal of Clinical Practice, vol.60, issue.5, pp.613-620, 2006. ,
Duloxetine 60 mg once daily in the treatment of milder major depressive disorder, International Journal of Clinical Practice, vol.60, issue.5, pp.613-620, 2006. ,
The ?Assigned Residence? Case: H.C. 7015, 7019/02 Kipah Ajuri et al. v. IDF Commander in The West Bank et al., Israel Law Review, vol.36, issue.1, pp.179-195, 2002. ,
Duloxetine 60 mg once daily in the treatment of milder major depressive disorder, International Journal of Clinical Practice, vol.60, issue.5, pp.613-620, 2006. ,
P.1.160 Duloxetine for the treatment of major depressive disorder: Safety and efficacy associated with rapid dose escalation (60?120 mg QD), European Neuropsychopharmacology, vol.13, p.S242, 2003. ,
,
Time to response for duloxetine 60 mg once daily versus placebo in elderly patients with major depressive disorder, International Psychogeriatrics, vol.20, issue.02, 2007. ,
P.1.160 Duloxetine for the treatment of major depressive disorder: Safety and efficacy associated with rapid dose escalation (60?120 mg QD), European Neuropsychopharmacology, vol.13, issue.8, p.S242, 2003. ,
A Review of Duloxetine 60 mg Once-Daily Dosing for the Management of Diabetic Peripheral Neuropathic Pain, Fibromyalgia, and Chronic Musculoskeletal Pain Due to Chronic Osteoarthritis Pain and Low Back Pain, Pain Practice, vol.13, issue.3, pp.239-252, 2012. ,
P.1.c.012 Efficacy and safety of duloxetine 60-mg and 120-mg daily in patients hospitalised for severe depression, European Neuropsychopharmacology, vol.19, issue.5, p.S258, 2009. ,
Lidocaine/magnesium, Reactions Weekly, vol.1508, issue.1, pp.23-23, 2014. ,
P.1.160 Duloxetine for the treatment of major depressive disorder: Safety and efficacy associated with rapid dose escalation (60?120 mg QD), European Neuropsychopharmacology, vol.13, p.S242, 2003. ,
P.1.160 Duloxetine for the treatment of major depressive disorder: Safety and efficacy associated with rapid dose escalation (60?120 mg QD), European Neuropsychopharmacology, vol.13, issue.1, p.S242, 2003. ,